| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_94a9d73cd541a05281d896294280296d |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7072
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7004
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7012
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7072
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P21-00 |
| filingDate |
2015-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b03956d85bd0ec24ccb8815f32bdd486 |
| publicationDate |
2016-02-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2016028894-A1 |
| titleOfInvention |
Treatment of glycosylation deficiency diseases |
| abstract |
Uridine triacetate or other uridine prodrugs are used to treat genetic glycosylation disorders by administering them in an amount sufficient to raise plasma uridine in the to a level greater than 30 micromolar. They can be administered alone or in combination with a sugar whose transfer is defective in the glycosylation disorder being treated. |
| priorityDate |
2014-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |